Robert Mulroy

Robert Mulroy

Chief Executive Officer

Bob serves as a director and the Chief Executive Officer of PTx. He has 25 years of experience in the biopharmaceutical and healthcare sector, having led the development of multiple biotech companies and served as an industry consultant. Prior to PTx, he served as a co-founder, CEO, president, and director of Merrimack and a director and CEO of Atlantic Biosciences. He has extensive experience in a complete range of capital transactions, capital raising, global business development, and organizational capability building. Bob earned his undergraduate degree from Stanford and his Masters in Public and Private Management at Yale.

Dr-Roychowdhury

Debasish Roychowdhury, MD

Chief Technology Officer

Debasish serves as a director and the Chief Medical Officer of PTx. Debasish is a medical oncologist and a proven leader in the pharmaceutical industry with over 15 years of industry senior management experience and 14 years of patient care, academic research and teaching experience. Prior to PTx, he served as the Chief Medical Officer of Seragon through the company’s acquisition by Roche. Prior to Seragon, Debasish served as the Senior Vice President and Head of the Global Oncology Division at Sanofi, the Vice President for Clinical Development at GlaxoSmithKline, and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati. He trained at the All India Institute of Medical Sciences and University of California, San Francisco. Debasish is a member of the Board of Directors for Radius Health, Celyad, Lytix Biopharma AS and Fund+.

Sarah Kurz

Sarah Kurz

Chief Commercialization Officer and Head of Medical Affairs

Sarah leads PTx’s commercial organization and brings to this role experience in the pharmaceutical industry that spans field leadership, commercial operations, analytics and strategy. She has launched multiple products, served as an Executive Committee member, and led cross-functional teams driving products to approval and overseeing strategic corporate initiatives. Prior to joining PTx, Sarah led the commercial effort at Merrimack, served as the head of strategy and business intelligence at Ipsen, and was the team leader for a phase 3 asset at MacroGenics while leading their program management function. She holds an undergraduate degree from Bowdoin College and both an MBA and MPH from Emory University.

BillMcClements2

Bill McClements

Chief Financial and Operations Officer

Bill serves as PTx’s Chief Financial and Operations Officer. For over twenty years, Bill helped to lead and build the Monitor Group, a global strategic advisory firm, where he served as a Partner, Executive Committee member and Chief Operating Officer. Prior to PTx, he served as Senior Vice President of Corporate Operations at Merrimack Pharmaceuticals. Bill holds an MBA from Harvard Business School and a BA from Williams College.

David-Carlson

Dave Carlson

Vice President Manufacturing

Dave serves as the head of manufacturing for PTx. He has 30 years of biologic manufacturing experience. Most recently, Dave served as the site head under Sanofi for the Northpointe manufacturing facility in Lynnwood, Washington. He held similar management posts under Genzyme, Bayer, and Berlex overseeing manufacturing operations. Dave started his career with Immunex and holds BS in microbiology from Oregon State University.

JohnMcManus2

John McManus

Chief Business Officer

John serves as PTx’s Chief Business Officer. He has 20 years of leadership experience in the biopharmaceutical industry, that includes leading the transformation of several biotech companies through strategic partnerships and execution of value based strategies. Prior to joining PTx, John was the CEO of Aeolus Pharmaceuticals, where he managed a $100+ million BARDA contract for the advanced development of a radiation medical countermeasure. Before joining Aeolus, John served in strategic and financial roles at Spectrum Pharmaceuticals where he focused on oncology and NeoTherapeutics where he focused on Alzheimer’s, Parkinson’s, ALS and spinal cord injury. John holds a B.S. in International Finance and Business Economics from the University of Southern California.

Ed Rock

Ed Rock

Chief Medical Officer

Ed serves as Chief Medical Officer for PTx.  Ed brings over 16 years of biopharmaceutical leadership experience in clinical development. Prior to joining PTx, Ed led the clinical development and BLA submission of the Phase 3 SOPHIA trial while VP of Clinical Research at Macrogenics. Prior to this, Ed served in clinical development leadership roles at Astex Pharmaceuticals, Otsuka, and GSK.  Before moving to industry, he also served as a Medical Officer in oncology drug review at the US FDA.  Ed holds a B.A. in Biology and Economics from Swarthmore College, as well as PhD in Microbiology and Immunology and MD degrees from the Stanford University School of Medicine. He completed medical residency training at Brigham and Women’s Hospital in Boston, MA, a medical oncology fellowship at the University of Pennsylvania, and a postdoctoral fellowship in vaccine engineering at Stanford.